Anti-Breast Cancer Effects of Vitamin D3 Analogs Either Alone or in Combination with Other Agents
Abstract
We have studied the effects of various Vitamin D analogs alone and in combination against breast cancer cells. We have found the vitamin D analog EB1089 to be particularly potent against in vivo breast cancer cells (MCF-7), without causing hypercalcemia or other major side-effects. An additive effect was observed when a vitamin D analog and Taxol were administered together. EB1089 plus Taxol was the most active combination. Our studies have also demonstrated that a peroxisome proliferator activated receptor gamma (PPARy) ligand (Troglitazone) has chemopreventive properties in breast cancer. The addition of a RXR-selective ligand appears to enhance this activity. Cyr61 is a gene that has been identified in other tissue types and is associated with angiogenesis and metastasis. We have identified prominent expression of the Cyr61 gene in selected breast cancer cell lines as well as in fresh breast tumors. When we exposed normal breast cells to estrogen and an anti-estrogen, we altered expression of this gene.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1999
- Accession Number
- ADA381252
Entities
People
- H. P. Koeffler
Organizations
- Cedars-Sinai Medical Center